JP2018521121A - （ｚ）−４−（５−（（３−ベンジル−４−オキソ−２−チオキソチアゾリジン−５−イリデン）メチル）フラン−２−イル）安息香酸の固体形状 - Google Patents
（ｚ）−４−（５−（（３−ベンジル−４−オキソ−２−チオキソチアゾリジン−５−イリデン）メチル）フラン−２−イル）安息香酸の固体形状 Download PDFInfo
- Publication number
- JP2018521121A JP2018521121A JP2018516398A JP2018516398A JP2018521121A JP 2018521121 A JP2018521121 A JP 2018521121A JP 2018516398 A JP2018516398 A JP 2018516398A JP 2018516398 A JP2018516398 A JP 2018516398A JP 2018521121 A JP2018521121 A JP 2018521121A
- Authority
- JP
- Japan
- Prior art keywords
- xrpd
- diffractometer
- radiation
- measured
- pattern
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
- C07C215/02—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C215/04—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated
- C07C215/06—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic
- C07C215/08—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic with only one hydroxy group and one amino group bound to the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
- C07C215/02—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C215/04—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated
- C07C215/06—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic
- C07C215/10—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic with one amino group and at least two hydroxy groups bound to the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
- C07C215/02—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C215/40—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton with quaternised nitrogen atoms bound to carbon atoms of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562175066P | 2015-06-12 | 2015-06-12 | |
| US62/175,066 | 2015-06-12 | ||
| US201662275655P | 2016-01-06 | 2016-01-06 | |
| US62/275,655 | 2016-01-06 | ||
| PCT/US2016/037067 WO2016201356A1 (en) | 2015-06-12 | 2016-06-10 | Solid forms of (z)-4-(5-((3-benzyl-4-oxo-2-thioxothiazolidin-5-ylidene)methyl)furan-2-yl)benzoic acid |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018521121A true JP2018521121A (ja) | 2018-08-02 |
| JP2018521121A5 JP2018521121A5 (enExample) | 2019-07-18 |
Family
ID=57504544
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018516398A Pending JP2018521121A (ja) | 2015-06-12 | 2016-06-10 | （ｚ）−４−（５−（（３−ベンジル−４−オキソ−２−チオキソチアゾリジン−５−イリデン）メチル）フラン−２−イル）安息香酸の固体形状 |
Country Status (12)
| Country | Link |
|---|---|
| US (4) | US10723726B2 (enExample) |
| EP (1) | EP3307722B1 (enExample) |
| JP (1) | JP2018521121A (enExample) |
| KR (1) | KR102663856B1 (enExample) |
| CN (1) | CN107848991B (enExample) |
| AU (2) | AU2016275125A1 (enExample) |
| BR (2) | BR112017026406A2 (enExample) |
| CA (2) | CA3221219A1 (enExample) |
| ES (1) | ES2896674T3 (enExample) |
| IL (1) | IL256237B (enExample) |
| SG (1) | SG10201911442XA (enExample) |
| WO (1) | WO2016201356A1 (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2025529972A (ja) * | 2022-09-02 | 2025-09-09 | レックスファームテック カンパニー リミテッド | 新規ベンフォチアミンコリン塩 |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3307722B1 (en) | 2015-06-12 | 2021-08-04 | GB006, Inc. | Solid forms of (z)-4-(5-((3-benzyl-4-oxo-2-thioxothiazolidin-5-ylidene)methyl)furan-2-yl)benzoic acid |
| US20200123146A1 (en) * | 2016-12-29 | 2020-04-23 | Gb006, Inc. | Heterocyclic integrin agonists |
| DK3601265T3 (da) * | 2017-03-30 | 2023-09-18 | Merck Patent Gmbh | Fast form af (s)-[2-chlor-4-fluor-5-(7-morpholin-4-ylquinazolin-4-yl)phenyl]-(6-methoxy-pyridazin-3-yl)methanol |
| TW202024061A (zh) | 2017-08-17 | 2020-07-01 | 美商基利科學股份有限公司 | Hiv蛋白質膜抑制劑之固體形式 |
| CA3103522C (en) | 2018-07-16 | 2023-11-21 | Gilead Sciences, Inc. | Capsid inhibitors for the treatment of hiv |
| EP3889136B1 (en) | 2018-11-28 | 2024-12-18 | Luoxin Pharmaceutical (Shanghai) Co., Ltd. | Salt form of estrogen receptor downregulator, crystalline form thereof, and preparation method therefor |
| WO2020236667A1 (en) * | 2019-05-17 | 2020-11-26 | Gb006, Inc. | Methods of treating cancer |
| WO2021061665A1 (en) * | 2019-09-23 | 2021-04-01 | Gb006, Inc. | Integrin agonist prodrugs |
| WO2021096988A1 (en) | 2019-11-12 | 2021-05-20 | Gb006, Inc. | Crystalline salt forms of (z)-4-(5-((3-benzyl-4-oxo-2-thioxothiazolidin-5-ylidene)methyl)furan-2-yl)benzoic acid |
| WO2023039170A1 (en) * | 2021-09-09 | 2023-03-16 | Musc Foundation For Research Development | Selective targeting of cd38 activity as an immunostimulatory and antitumor strategy |
| WO2024081449A1 (en) * | 2022-10-14 | 2024-04-18 | Rush University Medical Center | Cd11b agonists for treatment of autoimmune disease |
| CN121197154B (zh) * | 2025-11-13 | 2026-06-23 | 首都医科大学附属北京天坛医院 | Mac-1激动剂在制备治疗和/或缓解脑出血药物中的应用 |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040002526A1 (en) * | 2002-04-03 | 2004-01-01 | Cell Therapeutics, Inc. | Phospholipase D inhibitors and uses thereof |
| JP2007509159A (ja) * | 2003-10-22 | 2007-04-12 | スミスクライン・ビーチャム・コーポレイション | ２−（３，４−ジメチルフェニル）−４−｛［２−ヒドロキシ−３’−（１ｈ−テトラゾール−５−イル）ビフェニル−３−イル］−ヒドラゾノ｝−５−メチル−２，４−ジヒドロピラゾール−３−オン・コリン |
| US20080033025A1 (en) * | 2004-09-23 | 2008-02-07 | Maurizio Pellecchia | Inhibition of lethal factor protease activity from anthrax toxin |
| WO2008091532A1 (en) * | 2007-01-19 | 2008-07-31 | Panacos Pharmaceuticals, Inc. | Salts of 3-o-(3',3'-dimethylsuccinyl)betulinic acid and solid state forms thereof |
| JP2013536162A (ja) * | 2010-07-08 | 2013-09-19 | アダール ファーマシューティカルズ インコーポレイテッド | インテグリンＣＤ１１ｂ／ＣＤ１８を調節するための化合物及び方法 |
| WO2013159082A1 (en) * | 2012-04-20 | 2013-10-24 | Adhaere Pharmaceuticals, Inc. | Compounds and methods for regulating integrins |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1654380A4 (en) | 2003-08-14 | 2009-09-09 | Insight Biopharmaceuticals Ltd | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR MODULATING HEPARANASE ACTIVATION AND USES THEREOF |
| FI20041129A0 (fi) | 2004-08-30 | 2004-08-30 | Ctt Cancer Targeting Tech Oy | Tioksotiatsolidinoniyhdisteitä lääkkeinä käytettäviksi |
| ITMI20042475A1 (it) * | 2004-12-23 | 2005-03-23 | Cell Therapeutics Europe Srl | Uso di derivati tiazolidinonici come agenti terapeutici |
| WO2008005651A2 (en) * | 2006-06-08 | 2008-01-10 | Decode Chemistry, Inc. | Cyclic carboxylic acid rhodanine derivatives for the treatment and prevention of tuberculosis |
| WO2008082537A2 (en) | 2006-12-19 | 2008-07-10 | The General Hospital Corporation | Compounds for modulating integrin cd11b/cd18 |
| CN103159695B (zh) * | 2011-12-08 | 2015-08-12 | 首都师范大学 | 可抑制hiv复制并对耐药hiv病毒株有效的噻唑类化合物及其制备方法和用途 |
| EP3307722B1 (en) | 2015-06-12 | 2021-08-04 | GB006, Inc. | Solid forms of (z)-4-(5-((3-benzyl-4-oxo-2-thioxothiazolidin-5-ylidene)methyl)furan-2-yl)benzoic acid |
-
2016
- 2016-06-10 EP EP16808465.5A patent/EP3307722B1/en active Active
- 2016-06-10 BR BR112017026406-4A patent/BR112017026406A2/pt not_active Application Discontinuation
- 2016-06-10 KR KR1020177037752A patent/KR102663856B1/ko active Active
- 2016-06-10 CA CA3221219A patent/CA3221219A1/en active Pending
- 2016-06-10 BR BR122023025347-7A patent/BR122023025347A2/pt not_active Application Discontinuation
- 2016-06-10 CN CN201680041800.5A patent/CN107848991B/zh active Active
- 2016-06-10 AU AU2016275125A patent/AU2016275125A1/en not_active Abandoned
- 2016-06-10 SG SG10201911442XA patent/SG10201911442XA/en unknown
- 2016-06-10 WO PCT/US2016/037067 patent/WO2016201356A1/en not_active Ceased
- 2016-06-10 ES ES16808465T patent/ES2896674T3/es active Active
- 2016-06-10 US US15/735,560 patent/US10723726B2/en active Active
- 2016-06-10 JP JP2018516398A patent/JP2018521121A/ja active Pending
- 2016-06-10 CA CA2988584A patent/CA2988584C/en active Active
-
2017
- 2017-12-11 IL IL256237A patent/IL256237B/en unknown
-
2019
- 2019-11-05 US US16/675,097 patent/US11111239B2/en active Active
-
2020
- 2020-11-16 AU AU2020270457A patent/AU2020270457B2/en active Active
-
2022
- 2022-11-01 US US17/978,848 patent/US12227497B2/en active Active
-
2025
- 2025-01-09 US US19/015,307 patent/US20250353840A1/en active Pending
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040002526A1 (en) * | 2002-04-03 | 2004-01-01 | Cell Therapeutics, Inc. | Phospholipase D inhibitors and uses thereof |
| JP2007509159A (ja) * | 2003-10-22 | 2007-04-12 | スミスクライン・ビーチャム・コーポレイション | ２−（３，４−ジメチルフェニル）−４−｛［２−ヒドロキシ−３’−（１ｈ−テトラゾール−５−イル）ビフェニル−３−イル］−ヒドラゾノ｝−５−メチル−２，４−ジヒドロピラゾール−３−オン・コリン |
| US20080033025A1 (en) * | 2004-09-23 | 2008-02-07 | Maurizio Pellecchia | Inhibition of lethal factor protease activity from anthrax toxin |
| WO2008091532A1 (en) * | 2007-01-19 | 2008-07-31 | Panacos Pharmaceuticals, Inc. | Salts of 3-o-(3',3'-dimethylsuccinyl)betulinic acid and solid state forms thereof |
| JP2013536162A (ja) * | 2010-07-08 | 2013-09-19 | アダール ファーマシューティカルズ インコーポレイテッド | インテグリンＣＤ１１ｂ／ＣＤ１８を調節するための化合物及び方法 |
| WO2013159082A1 (en) * | 2012-04-20 | 2013-10-24 | Adhaere Pharmaceuticals, Inc. | Compounds and methods for regulating integrins |
Non-Patent Citations (5)
| Title |
|---|
| JOURNAL OF PHARMACEUTICAL SCIENCES, vol. 66, no. 1, JPN5012008762, 1977, pages 1 - 19, ISSN: 0004700993 * |
| 仲井由宣 花野学編, 新製剤学, vol. 第１版第２刷, JPN6016032041, 25 April 1984 (1984-04-25), pages 102 - 104, ISSN: 0004700994 * |
| 塩路雄作, 固形製剤の製造技術, vol. 普及版第１刷, JPN6016031894, 27 January 2003 (2003-01-27), pages 9 - 14, ISSN: 0004700995 * |
| 平山令明編著, 有機化合物結晶作製ハンドブック−原理とノウハウ−, JPN6016031902, 25 July 2008 (2008-07-25), pages 37 - 84, ISSN: 0004700996 * |
| 社団法人日本化学会編, 第４版 実験化学講座１ 基本操作Ｉ, vol. 第２刷, JPN6016031896, 5 April 1996 (1996-04-05), pages 184 - 186, ISSN: 0004700997 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2025529972A (ja) * | 2022-09-02 | 2025-09-09 | レックスファームテック カンパニー リミテッド | 新規ベンフォチアミンコリン塩 |
Also Published As
| Publication number | Publication date |
|---|---|
| AU2016275125A1 (en) | 2018-01-25 |
| US10723726B2 (en) | 2020-07-28 |
| NZ738836A (en) | 2024-03-22 |
| EP3307722B1 (en) | 2021-08-04 |
| BR122023025347A2 (pt) | 2024-01-16 |
| AU2020270457A1 (en) | 2020-12-10 |
| US20180354938A1 (en) | 2018-12-13 |
| US20200317657A1 (en) | 2020-10-08 |
| IL256237B (en) | 2021-12-01 |
| CA2988584A1 (en) | 2016-12-15 |
| US12227497B2 (en) | 2025-02-18 |
| WO2016201356A1 (en) | 2016-12-15 |
| SG10201911442XA (en) | 2020-02-27 |
| KR102663856B1 (ko) | 2024-05-07 |
| CN107848991A (zh) | 2018-03-27 |
| US20250353840A1 (en) | 2025-11-20 |
| EP3307722A1 (en) | 2018-04-18 |
| ES2896674T3 (es) | 2022-02-25 |
| AU2020270457B2 (en) | 2022-10-20 |
| IL256237A (en) | 2018-02-28 |
| CN107848991B (zh) | 2022-01-14 |
| KR20180016443A (ko) | 2018-02-14 |
| US20230227443A1 (en) | 2023-07-20 |
| CA2988584C (en) | 2024-01-23 |
| CA3221219A1 (en) | 2016-12-15 |
| US11111239B2 (en) | 2021-09-07 |
| BR112017026406A2 (pt) | 2019-04-02 |
| EP3307722A4 (en) | 2018-12-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12227497B2 (en) | Solid forms of(Z)-4-(5-((3-benzyl-4-oxo-2-thioxothiazolidin-5-ylidene)methyl)furan-2-yl)benzoic acid | |
| US11149043B2 (en) | Prodrug modulators of the integrated stress pathway | |
| UA128792C2 (uk) | ПОХІДНІ ТЕТРАГІДРО-1Н-ЦИКЛОПЕНТА[cd]ІНДЕНУ ЯК ІНГІБІТОРИ ФАКТОРА-2(АЛЬФА), ЩО ІНДУКУЄТЬСЯ ГІПОКСІЄЮ | |
| JP2021501790A (ja) | 統合的ストレス経路の調節剤 | |
| TW202216698A (zh) | Cdk4抑制劑之固體形式 | |
| JP2021501785A (ja) | 統合的ストレス経路の調節剤 | |
| JP2021501788A (ja) | 統合的ストレス経路の調節剤 | |
| JP7690284B2 (ja) | Ｉｄｏ阻害剤の非晶質形態および結晶形態 | |
| JP2020526520A5 (enExample) | ||
| KR20240090359A (ko) | 3-플루오로-5-(((1S,2aR)-1,3,3,4,4-펜타플루오로-2a-하이드록시-2,2a,3,4-테트라하이드로-1H-사이클로펜타[CD]인덴-7-일)옥시)-벤조니트릴및 이의 다형을 제조하는 프로세스 | |
| JP2022518175A (ja) | （ｓ）－４－（４－（４－（（（２－（２，６－ジオキソピペリジン－３－イル）－１－オキソイソインドリン－４－イル）オキシ）メチル）ベンジル）ピペラジン－１－イル）－３－フルオロベンゾニトリルを含む固体形態及びその塩、ならびにそれらを含む組成物及びその使用方法 | |
| IL324207A (en) | Irak inhibitor free base, salts, and polymorphic forms thereof | |
| EA049146B1 (ru) | Аморфные и кристаллические формы ido-ингибиторов | |
| EA041037B1 (ru) | Аморфные и кристаллические формы ido-ингибиторов | |
| BR112021006789B1 (pt) | Moduladores de pró-fármaco da via de estresse integrada |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190610 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20190610 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20200605 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20200630 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20200929 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210104 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20210406 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20210705 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20220208 |